Viruses as Medicine
Mumps and ovarian cancer: modern interpretation of an historic association
"Mumps parotitis may lead to expression and immune recognition of a tumor-associated form of MUC1 and create effective immune surveillance of ovarian cancer cells that express this form of MUC1."
So found researchers at Harvard Medical School. They published their findings in the August, 2010 issue of the journal, "Cancer Causes Control."
There is a growing body of evidence that natural infections early in life are essential for training the immune system to deal with more difficult challenges later in life. These researchers have found some of this evidence.
Click here to read their study.
So found researchers at Harvard Medical School. They published their findings in the August, 2010 issue of the journal, "Cancer Causes Control."
There is a growing body of evidence that natural infections early in life are essential for training the immune system to deal with more difficult challenges later in life. These researchers have found some of this evidence.
Click here to read their study.
Measles and mumps associated with lower risk of mortality from heart disease
"Measles and mumps, especially in case of both infections, were associated with lower risks of mortality from atherosclerotic CVD."
So found researchers at the Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Click here to read the abstract of their findings published in the August, 2015 issue of the journal, "Atherosclerosis."
So found researchers at the Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Click here to read the abstract of their findings published in the August, 2015 issue of the journal, "Atherosclerosis."
Natural Chicken Pox Infection Reduces Risk of Brain Cancer
"We found that a positive history of chickenpox was associated with a 21% lower glioma risk. Furthermore, the protective effect of chickenpox was stronger for high-grade gliomas.
Our study provides additional evidence that the observed protective effect of chickenpox against glioma is unlikely to be coincidental."
http://onlinelibrary.wiley.com/doi/10.1002/cam4.682/full
Our study provides additional evidence that the observed protective effect of chickenpox against glioma is unlikely to be coincidental."
http://onlinelibrary.wiley.com/doi/10.1002/cam4.682/full
Annual vaccination against influenza virus hampers development of virus-specific CD8⁺ T cell immunity in children.
So found researchers in the Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands. They published their findings in the November, 2011 issue of the "Journal of Virology."
Click here to read their full report.
Click here to read their full report.
Patentable, genetically engineered versions of measles used to treat cancer
The Mayo Clinic is finding that measles virus can cure cancer. They used a patented strain. We can't help wondering what the difference might be between the effectiveness of a patented strain and a natural, unpatentable strain, between using the patented version as medicine once the illness has set in and using the natural infection in the natural way to prevent the illness altogether.
"Two patients in the study received a single intravenous dose of an engineered measles virus (MV-NIS) that is selectively toxic to myeloma plasma cells. Both patients responded, showing reduction of both bone marrow cancer and myeloma protein. One patient, a 49-year-old woman, experienced complete remission of myeloma and has been clear of the disease for over six months.
'This is the first study to establish the feasibility of systemic oncolytic virotherapy for disseminated cancer,' says Stephen Russell, M.D., Ph.D., Mayo Clinic hematologist, first author of the paper and co-developer of the therapy. 'These patients were not responsive to other therapies and had experienced several recurrences of their disease.'”
Click here to read the article on the Mayo Clinic website.
Click here to read the abstract of the study, published in July, 2014 in the "Mayo Clinic Proceedings."
"Two patients in the study received a single intravenous dose of an engineered measles virus (MV-NIS) that is selectively toxic to myeloma plasma cells. Both patients responded, showing reduction of both bone marrow cancer and myeloma protein. One patient, a 49-year-old woman, experienced complete remission of myeloma and has been clear of the disease for over six months.
'This is the first study to establish the feasibility of systemic oncolytic virotherapy for disseminated cancer,' says Stephen Russell, M.D., Ph.D., Mayo Clinic hematologist, first author of the paper and co-developer of the therapy. 'These patients were not responsive to other therapies and had experienced several recurrences of their disease.'”
Click here to read the article on the Mayo Clinic website.
Click here to read the abstract of the study, published in July, 2014 in the "Mayo Clinic Proceedings."